| Ajovy (fremanezumab-vfrm) / Teva |
2020-004509-30: Changes in advance MRI on migraine patients treated with fremanezumab Cambios en la resonancia magnética anticipada de los pacientes con migraña tratados con fremanezumab |
|
|
| Not yet recruiting | 4 | 87 | Europe | FREMANEZUMAB, EMEA/H/C/004833, Solution for injection in pre-filled syringe, AJOVY 225 mg solución inyectable en jeringa precargada | INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON, INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON | MIGRAINE Migraña, MIGRAINE Migraña, Diseases [C] - Nervous System Diseases [C10] | | | | |
2021-006219-28: MR-Spectroscopy Study: Investigating changes in brain metabolism in migraine patients before and after therapeutic influence |
|
|
| Ongoing | 4 | 38 | Europe | Ajovy, Solution for injection in pre-filled syringe, Ajovy | Medical University Innsbruck, TEVA | Episodic migraine, Episodic migraine, Not possible to specify | | | | |
| Terminated | 4 | 32 | US | Eptinezumab, Vyepti, Erenumab, Aimovig®, Onabotulinumtoxin-A, Fremanezumab, Ajovy®, Galcanezumab, Emgality® | H. Lundbeck A/S | Migraine | 02/23 | 04/23 | | |
| Recruiting | 4 | 87 | Europe | Fremanezumab Prefilled Syringe | Hospital Clínico Universitario de Valladolid, University of Valladolid, Complejo Asistencial Universitario de Palencia, Complejo Público Asistencial de Zamora | Migraine Disorders, Migraine With Aura, Migraine Without Aura, Brain Diseases | 10/24 | 01/25 | | |
COACT, NCT05724771: Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study |
|
|
| Active, not recruiting | 4 | 50 | US | Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL) | Chicago Headache Center & Research Institute | Chronic Migraine, Headache | 03/25 | 05/25 | | |
NCT06173661: Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 |
|
|
| Recruiting | 4 | 72 | US | Fremanezumab, AJOVY, Placebo | Brigham and Women's Hospital, Teva Pharmaceuticals USA | Migraine, Menstrual Migraine, Menstrually Related Migraine | 01/26 | 07/26 | | |
| Recruiting | 4 | 100 | US | Fremanezumab Prefilled Syringe [Ajovy] | Beth Israel Deaconess Medical Center, Teva Pharmaceuticals USA | Migraine Disorders, Sleep Disorder | 05/24 | 05/24 | | |
NCT05458011: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine |
|
|
| Completed | 3 | 365 | RoW | Fremanezumab, TEV-48125, Ajovy, Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Migraine | 01/24 | 06/24 | | |
| Completed | 3 | 235 | Europe, Canada, US, RoW | Fremanezumab, Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Migraine | 03/24 | 03/24 | | |
| Completed | 3 | 298 | Europe, Canada, US, RoW | Fremanezumab, Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Migraine | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 476 | Europe, Canada, US, RoW | Fremanezumab | Teva Branded Pharmaceutical Products R&D, Inc. | Migraine | 11/25 | 03/26 | | |
NCT04547179: Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study |
|
|
| Not yet recruiting | N/A | 80 | US | Fremanezumab-Vfrm, Ajovy®, BLAfit®, Bella Lip Appliance®, BLA®, Saline, salt and water solution | Manhattan Beach Orthodontics | Migraine | 04/21 | 12/21 | | |
NCT03539393: Fremanezumab Compassionate Use Program for Pediatric Patients |
|
|
| Available | N/A | | NA | Fremanezumab, TEV-48125 | Teva Branded Pharmaceutical Products R&D, Inc. | Migraine | | | | |
NCT04788667: Effectiveness of a Health Education Programme for Prevention of Chronic Migraine: A Randomized Clinical Trial |
|
|
| Completed | N/A | 48 | Europe | A health education programme using a telerehabilitation platform, Regular pharmacological treatment provided by their neurologists (Fremanezumab o Erenumab), Regular pharmacological treatment provided by their neurologists (Botulinum Toxin) | Universidad de Zaragoza, Universidad San Jorge, Hospital Clínico Universitario Lozano Blesa | Chronic Migraine | 04/24 | 07/24 | | |
| Recruiting | N/A | 120 | Europe | Erenumab, Aimovig®, Galcanezumab, Emgality®, Fremanezumab, Ajovy® | Medical University of Vienna | Episodic Migraine, Chronic Migraine | 12/25 | 12/26 | | |
NCT06212661: Migraine Medication Effects on Urinary Symptoms |
|
|
| Enrolling by invitation | N/A | 200 | US | Ubrogepant, Ubrelvy, Rimegepant, Nurtec, Atogepant, Qulipta, Eptinezumab, Vyepti, Fremanezumab, Ajovy, Galcanezumab, Emgality, Erenumab, Aimovig, Botulinum toxin A, Botox | The Cleveland Clinic | Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis | 05/25 | 05/26 | | |
| Recruiting | N/A | 120 | Europe | Fremanezumab | Insel Gruppe AG, University Hospital Bern | Menstrual Migraine | 12/26 | 03/27 | | |
NCT05281770: Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study |
|
|
| Recruiting | N/A | 1500 | Europe | Erenumab, Fremanezumab, Galcanezumab | Austrian Migraine Registry Collaboration, Medical University of Vienna, Medical University Innsbruck, Austrian Headache Society | Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine, Episodic Migraine | 09/25 | 12/25 | | |
NCT05342493: Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use |
|
|
| Recruiting | N/A | 1000 | Japan | Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution | Otsuka Pharmaceutical Co., Ltd. | Migraine Disorders | 09/26 | 06/29 | | |
